Cannabigerol proline cocrystals
AssigneeManoira Corporation
InventorsJoanne Holland, Alex Eberlin
Life of this patent
Estimating the term…
Abstract
Cannabigerol proline cocrystals are disclosed, specifically a 1:2 cannabigerol L-proline cocrystal, a 1:2 cannabigerol D-proline cocrystal and a 1:2 cannabigerol D, L-proline cocrystal and their preparation. Also disclosed are pharmaceutical compositions containing a cannabigerol proline cocrystal and a pharmaceutically acceptable excipient as well as methods and uses of a cannabigerol proline cocrystal or pharmaceutical composition to treat a disease, disorder or condition by administering to a patient in need thereof a therapeutically effective amount of a cannabigerol proline cocrystal or a pharmaceutical composition containing a cannabigerol proline cocrystal. Also disclosed are processes for the preparation of crystalline cannabigerol, Forms I, II and III.
Claims5
A cannabigerol proline cocrystal selected from the group of 1:2 cannabigerol L-proline cocrystal, 1:2 cannabigerol D-proline cocrystal and 1:2 cannabigerol D, L-proline cocrystal;
- wherein the cannabigerol proline cocrystal is characterized by:
- an X-ray powder diffraction pattern having peaks selected from 4.5, 7.8, 18.3 and 19.8° 2θ±0.2° 2θ;
- an X-ray powder diffraction pattern similar to FIG. 1;
- an infrared spectrum having at least four peaks selected from the peaks at 1625, 1597, 1429, 1307, 1280, 1224, 1166 and 1050 cm−1±1 cm−1;
- or
- an infrared spectrum similar to FIG. 2.
Dependencies are inferred from the claim text.